France’s Sanofi has entered into an exclusive licensing agreement with US biotechnology company RadioMedix and French biotechnology company Orano Med on radioligand therapies (RLTs) to treat cancer. The collaboration between Sanofi, RadioMedix and Orano Med focuses specifically on the late-stage project, AlphaMedix (Pb-212 dotamtate), which is currently being evaluated for the treatment of adult patients with rare neuroendocrine tumours.
Under the licensing agreement, Sanofi will be responsible for the global commercialisation of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development. RadioMedix and Orano Med will receive an upfront payment of €100m and up to €220m in sales milestones and be eligible for tiered royalties. This agreement is subject to standard regulatory approvals required for transactions of this nature.
“The Breakthrough Therapy Designation of AlphaMedix is a testament of its success in validating targeted alpha therapies, said Ebrahim S Delpassand, RadioMedix Chairman & CEO. “We see this as a potential for the future of nuclear oncology in general, and today it is pioneering next-generation treatment for patients with neuroendocrine tumours. In our research, we have seen that significantly higher energy delivery over much shorter path lengths in the tissue of alpha emitters can overcome the limitations of currently available beta emitter radioligand therapies. We believe Pb-212 is an ideal alpha emitter with highly desirable physical and supply characteristics compared with other alpha emitters.”
Julien Dodet, Orano Med President & CEO, said: “At Orano Med, we are at the forefront of innovation in radioligand therapy and are developing a global industrial platform for the manufacture and distribution of our Pb-212-conjugated drugs. This marks a pivotal moment to expedite the development of this new therapy and in our fight against cancer. Through this agreement, we aim to lead the charge in advancing radioligand therapies with the ambition to revolutionise cancer therapeutics.”
Sanofi said it remains committed to advancing oncology innovation. “Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress. Efforts are centred on difficult-to-treat cancers such as select hematologic malignancies, and solid tumours with critical unmet needs, including multiple myeloma, acute myeloid leukaemia, certain types of lymphomas, as well as gastrointestinal and lung cancers.”
